Cardio Diagnostics Holdings Inc (CDIO) Stock AnalysisCDIOStock AnalysisCardio Diagnostics Holdings Inc

Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Cardio Diagnostics Holdings Inc is not a strong buy at the moment due to its current price of 1.85, which is significantly lower than its 200-day simple moving average of 2.321. Additionally, the stock has a low RSI of 40.427, indicating it is not in an overbought condition, but the recent 5-day change of -8.87% suggests downward momentum. The main risk is the negative net income trend, with a reported loss of -1,501,468 in Q2 2026, which raises concerns about the company's profitability.